Radiofrequency ablation in Barrett's esophagus with dysplasia

Nicholas J. Shaheen, Prateek Sharma, Bergein F. Overholt, Herbert C. Wolfsen, Richard E. Sampliner, Kenneth K. Wang, Joseph A. Galanko, Mary P. Bronner, John R. Goldblum, Ana E. Bennett, Blair A. Jobe, Glenn M. Eisen, M. Brian Fennerty, John G. Hunter, David E. Fleischer, Virender K. Sharma, Robert H. Hawes, Brenda J. Hoffman, Richard I. Rothstein, Stuart R. GordonHiroshi Mashimo, Kenneth J. Chang, V. Raman Muthusamy, Steven A. Edmundowicz, Stuart J. Spechler, Ali A. Siddiqui, Rhonda F. Souza, Anthony Infantolino, Gary W. Falk, Michael B. Kimmey, Ryan D. Madanick, Amitabh Chak, Charles J. Lightdale

Research output: Contribution to journalArticle

946 Scopus citations

Abstract

BACKGROUND: Barrett's esophagus, a condition of intestinal metaplasia of the esophagus, is associated with an increased risk of esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic Barrett's esophagus and decrease the rate of neoplastic progression. METHODS: In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus in a 2:1 ratio to receive either radiofrequency ablation (ablation group) or a sham procedure (control group). Randomization was stratified according to the grade of dysplasia and the length of Barrett's esophagus. Primary outcomes at 12 months included the complete eradication of dysplasia and intestinal metaplasia. RESULTS: In the intention-to-treat analyses, among patients with low-grade dysplasia, complete eradication of dysplasia occurred in 90.5% of those in the ablation group, as compared with 22.7% of those in the control group (P<0.001). Among patients with high-grade dysplasia, complete eradication occurred in 81.0% of those in the ablation group, as compared with 19.0% of those in the control group (P<0.001). Overall, 77.4% of patients in the ablation group had complete eradication of intestinal metaplasia, as compared with 2.3% of those in the control group (P<0.001). Patients in the ablation group had less disease progression (3.6% vs. 16.3%, P = 0.03) and fewer cancers (1.2% vs. 9.3%, P = 0.045). Patients reported having more chest pain after the ablation procedure than after the sham procedure. In the ablation group, one patient had upper gastrointestinal hemorrhage, and five patients (6.0%) had esophageal stricture. CONCLUSIONS: In patients with dysplastic Barrett's esophagus, radiofrequency ablation was associated with a high rate of complete eradication of both dysplasia and intestinal metaplasia and a reduced risk of disease progression. (ClinicalTrials.gov number, NCT00282672.)

Original languageEnglish (US)
Pages (from-to)2277-2288
Number of pages12
JournalNew England Journal of Medicine
Volume360
Issue number22
DOIs
StatePublished - May 28 2009

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shaheen, N. J., Sharma, P., Overholt, B. F., Wolfsen, H. C., Sampliner, R. E., Wang, K. K., Galanko, J. A., Bronner, M. P., Goldblum, J. R., Bennett, A. E., Jobe, B. A., Eisen, G. M., Fennerty, M. B., Hunter, J. G., Fleischer, D. E., Sharma, V. K., Hawes, R. H., Hoffman, B. J., Rothstein, R. I., ... Lightdale, C. J. (2009). Radiofrequency ablation in Barrett's esophagus with dysplasia. New England Journal of Medicine, 360(22), 2277-2288. https://doi.org/10.1056/NEJMoa0808145